The median overall survival was @ months ( @ % confidence interval -LSB- CI -RSB- , @ to not reached ) in the group receiving the pertuzumab combination , as compared with @ months ( @ % CI , @ to @ ) in the group receiving the placebo combination ( hazard ratio favoring the pertuzumab group , @ ; @ % CI , @ to @ ; P < @ ) , a difference of @ months .